capillary endothelial cells and abnormal formation of new blood vessels in neoplasm
. Therefore, angiogenic inhibitor may hold great therapeutic potential in the treatment of solid tumour [4, 5] .
Some proteolytic fragments from human plasminogen are reported as angiogenic inhibitors. Kringle 5 (K5) is the fifth kringle domain of human plasminogen and has been widely demonstrated to inhibit proliferation of endothelial cells [6] . Moreover, its inhibitory activity is more potent than angiostatin that includes the first four kringle modules of plasminogen (kringles1-4) [6, 7] . In addition, K5 also inhibits endothelial cell migration, an important process in angiogenesis [8] , and exerts its effect on endothelial cells by inducing cell cycle arrest and apoptosis. We previously demonstrated the anti-angiogenic activity of K5 in rat model of oxygen-induced retinopathy (OIR) [9, 10] and rabbit model of alkali-burn-induced corneal neovascularization [11] . Recently, we proved the anti-tumour activity of K5 in hepatocarcinoma [12] . Down-regulation of VEGF and up-regulation of PEDF, thus leading toward restoration of the balance in angiogenic control, may represent a mechanism for the anti-angiogenic activity of K5 [13] .
To find more potent and smaller peptide sequence required for the anti-angiogenic activity and define the structure/function relationship of K5, two deletion mutants of K5 were generated in the present study according to the distribution of three disulfide bonds in intact K5. The amino acid residues outside kringle domain of K5 were deleted to form K5mut1 (Cys462-Cys541). The residue Cys462 was deleted again to form K5mut2 (Met463-Cys541). The disulfide bridging conformation and dimensional structure of recombinant K5 and mutants were predicted by 3D-JIGSAW Comparative Modelling Server (UK) and confirmed by mass spectrometry and circular dichroism (CD) analysis. Their anti-angiogenic and anti-hepatoma activities were evaluated both in vitro and in vivo. Our findings demonstrated for the first time that K5mut1 has more potent anti-angiogenic and anti-hepatoma activities than intact K5 and the complete kringle structure with appropriate folding of three disulfide bonds is required for the activity of K5.

Materials and methods
Construction and production of human plasminogen kringle 5 and its deletion mutants
The cDNAs encoding K5 and mutants were generated by polymerase chain reaction using a human plasminogen cDNA as the template with the following primers: K5 P 
(ϩ): 5Ј-TGTGAATTCGCCAGATGTAGAGACTCCTTC-3Ј, P(-):5Ј-GGAAAGCTTGGCACACTGAGGGACATCACAG-3Ј; K5mut1 P(ϩ): 5Ј-ATGAATTCGTGTATGTTTGGGAATGGG-3Ј, P(-):5Ј-GCCAAGCTTACACT-GAGGGACATCACAGTAG-3Ј; K5mut2 P(ϩ): 5Ј-CGGAATTCCAT-GTTTGGGAATGGGAAAGG-3Ј, P(-): 5Ј-CGGAAGCTTACACTGAGGGACAT-CACAGT-3Ј; K5mut3 P(ϩ):5Ј-ACTGAATTCGCCATCTGTATCGACTCCTTC-CTCATCATCCTGTATGTTTGG-3Ј, P(-)
:
Cell culture
Human umbilical vein endothelial cells (HUVEC) were freshly isolated from human umbilical cord veins, as previously described [16, 17] 
Cell proliferation assay
The viable cells were quantified by the 3- [4, 5- [12, 19] . The inhibitory effects of K5 on cell proliferation were expressed as IC50 values, which were determined from three independent tests.
Endothelial cell migration assay
Migration assays were performed as described previously [8, 20] 
Quantitative analysis of apoptosis by flow cytometry
Apoptosis analysis was carried out as described previously [12, 21, 22] 
Inhibition of liver cancer growth
Hepatocarcinoma mouse model was established as described previously by subcutaneously injection of mouse hepatoma cells (1ϫ10 6 ) into the oxter of mice [12] . [23, 24] . One month later from the first injection, the mice were executed and tumours were dissected, weighed.
Microvessel density assay
Immunostaining was performed as described previously with minor modification [16] . 
Results
Expression and purification of K5 and its deletion mutants
Two deletion mutants were designed according to the structure and disulfide bond distribution of K5 (Pro452-Ala542
More potent inhibiting effect of K5mut1 on endothelial cell migration
As shown in Fig. 3F (Fig. 3B-D) , suggesting their endothelial cell-specific inhibition.
Effects of K5 and K5mut1 on non-endothelial cell proliferation
The effects of K5 and K5mut1 on the proliferation of non-endothelial cell lines, including the normal liver cell line, human hepatocarcinoma cell lines Bel7402 and mouse hepatocarcinoma cell lines HepA was assayed. The results showed that both K5 and K5mut1 did not result in any significant inhibition of the three nonendothelial cell lines even in the higher concentration range
K5mut1 exhibits more potent anti-hepatoma effect
The anti-tumour activity of K5mut1 in vivo was determined in two kinds of animal models of liver cancer: the HepA-grafted hepatocarcinoma mice model and Bel7402-xenografted hepatocarcinoma athymic model. Compared with PBS injection control group, an average of 75% suppression of primary tumour growth was observed in the K5mut1-treated mice while intact K5 had 62%
growth suppression rate in HepA-grafted hepatocarcinoma mice model (Fig. 4A and B) . The effect of K5 and mutants on tumour angiogenesis was evaluated by CD31 immunostaining for capillaries in tumour tissues. The CD31 stained microvessel density in tumours treated with K5mut1 was lower than that in K5 group (Fig. 4C and D) . Similarly, an average of 77% suppression of primary tumour growth was observed in the K5mut1-treated mice and 68% suppression in intact K5-treated group in Bel7402-xenografted hepatocarcinoma athymic model (Fig. 5A and B) . Tumour angiogenesis was also evaluated in xenografted hepatocarcinoma athymic model. As same as that in HepA-grafted hepatocarcinoma, the CD31 stained microvessel density in xenografted tumours treated with K5mut1 was lower than that in K5 group (Fig. 5C and D 
). These results show that K5mut1, in comparison with intact K5, has an enhanced anti-hepatoma activity in two kinds of animal models of liver cancer. The more potent anti-hepatoma effect of K5mut1 might depend on the enhanced anti-angiogenic activity.
K5mut2 lacks the anti-angiogenesis and anti-tumour activity both in vitro and in vivo
Deletion mutant of K5 (K5mut2) was expressed and purified identically as recombinant K5 and K5mut1 protein (Fig. 1) (Fig. 3A, E and F) . Similar deficient effects of K5mut2 were found in hepatocarcinoma animal models mentioned above. In HepA-grafted hepatocarcinoma mice model, -7% suppression of primary tumour growth was observed in the K5mut2-treated group, whereas suppression percentage of K5 was 62% (Fig. 4) . Microvessel density in tumours treated with K5mut2 had no difference with that in PBS control group (Fig. 4C  and D) . Similarly, 9% suppression percentage observed in the K5mut2-treated mice was also markedly lower than intact K5 (68% suppression percentage) in Bel7402-xenografted hepatocarcinoma athymic model (Fig. 5) . As same as that in HepA-grafted hepatocarcinoma, K5mut2 had no effect on tumour angiogenesis (Fig. 5C and D) . These results show that K5mut2 lost the antiangiogenic and anti-tumour activities.
Acidic amino acid residues in NH 2 terminal outside kringle domain exert shielding effect on the activities of K5
K5mut3 (Pro452-Ala542) retained the intact kringle domain and the five acidic amino acids of the NH2 terminal prior to Cys462 of K5 were substituted by five serine residues (Fig. 6A) . K5mut3 was expressed, purified and identified identically as recombinant K5 (Fig. 6B and C) . (Fig. 6D) of a ␤-sheet with a single broad peak around 235 nm, suggesting that they share very similar secondary structures. K5mut1 adopt the shape characteristic of a ␤-sheet with a single broad peak around 230 nm. These results suggested that ␤-sheet is the structural feature for the activity of K5 and the function will disappear when ␤-sheet was converted into random coil structure.
The anti-angiogenic activity of K5mut3 was primarily measured by the analysis of endothelial cell proliferation with the positive control of K5-treated group. K5mut3 exhibited inhibition of endothelial cell proliferation in concentration-dependent manner (Fig. 6D). K5mut3 showed an IC50 of approximately 40 nmol/l while intact K5 has an IC50 of approximately 70 nmol/l in inhibiting HUVEC proliferation
Conformational analysis of K5 and mutants
Discussion
This present study shows that K5 and K5mut1 exert an antihepatoma activity both in HepA-grafted hepatocarcinoma mice model and Bel7402-xenografted hepatocarcinoma athymic model (Figs. 4 and 5) . Our previous study also demonstrated the antiangiogenic activity of K5 in rat model of OIR [9, 10] and rabbit model of alkali-burn-induced corneal neovascularization [11] . These results suggest that K5 and K5mut1 may be used in wide spectrum of angiogenic disorders such as solid tumours derived from different origins [15, 25] and ocular neovascularization. K5 and K5mut1 specific inhibit proliferation, migration and induce apoptosis and autophagy of endothelial cells [13, 14, 26] but has no effect on normal liver cells, HepA and Bel7402 hepatoma cell lines even in high range of concentration, suggesting its endothelial cell-specific inhibition (Fig. 3) . These universal effects of K5 and K5mut1 may be correlated with the common anti-endothelial cell activity.
Our study further shows that injection of recombinant K5mut1, in comparison with intact K5, has an enhanced inhibitory effect on hepatocellular carcinoma growth and neovascularization both in grafted and xenografted mice (Figs. 4 and 5 [7] . In contrast to Cao's results, Ji et al. described that alteration of K5 by reduction/alkylation significantly enhanced its anti-migratory potency [8] . In this study, peptide mapping of K5 (Fig. 2) . Our cysteine bridging pattern data confirm the finding of other studies that characterize the structure of recombinant K5 domain [15, 27] (Figs. 1A and 6A ). K5mut3 exhibited more potent inhibitory effect on endothelial cell proliferation than intact K5 (Fig. 6D) (Fig. 7) . The similar antiparallel ␤-sheet or parallel ␤-sheet structures were also observed via two-dimensional 1H-NMR analysis in the kringle 4 domain of equine and human plasminogen [27] , human apolipoprotein(a) kringle IV type 6 [28] and N-terminal kringle 1 of human hepatocyte growth factor [29] .
These results suggested that ␤-sheet is the general structural feature for the intact kringle domain and the function may change when ␤-sheet was converted into random coil structure.
In addition to K5, individual and multiple kringle fragments of angiostatin also show anti-proliferative activities and the disulfide bond-mediated appropriate folding of these kringle structures is required to maintain its anti-endothelial potency [5] . Kringle structures analogous to those in plasminogen are also found in a variety of other proteins [30] [31] [32] [33] [34] [35] . In general, a kringle is composed of 78-80 amino acids interconnected by a triple disulfide-linked loop. The triple disulfide bonds are strictly conserved between kringles [36] . Kringles derived from other molecules such as kringle 2 of prothrombin, kringles of human hepatocyte growth factor and uPA have been found to be angiogenic inhibitor [37] [38] [39] [40] 
